Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 11/20 | 0.51 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.36 |
| ▸ | PTPRB | P23467 | 1/20 | 0.36 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847289 | 0.96 | S1PR1 (0.55) | S1PR1S1PR3NOTUMLMNAKDM4E | |
| SCHEMBL3852867 | 0.94 | NOTUM (0.48) | S1PR1S1PR3NOTUMLMNAKDM4E | |
| SCHEMBL3857963 | 0.93 | S1PR1 (0.53) | S1PR1S1PR3NOTUMLMNAKDM4E | |
| SCHEMBL3850544 | 0.87 | S1PR1 (0.53) | S1PR1S1PR3 | |
| SCHEMBL3846493 | 0.85 | S1PR1 (0.69) | S1PR1S1PR3LMNAALDH1A1GAA | |
| SCHEMBL27654743 | 0.82 | S1PR1 (0.42) | S1PR1S1PR3SLC9A1PROKR1 | |
| SCHEMBL3849930 | 0.81 | S1PR1 (0.68) | S1PR1S1PR3LMNAALDH1A1GAA | |
| SCHEMBL3854580 | 0.81 | S1PR1 (0.75) | S1PR1S1PR3 | |
| SCHEMBL27674804 | 0.80 | S1PR1 (0.40) | S1PR1S1PR3LMNAALDH1A1GAA | |
| SCHEMBL3851878 | 0.79 | S1PR1 (0.56) | S1PR1S1PR3KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | claimed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | claimed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | claimed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | claimed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | claimed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| US-7572811-B2 | Immunosuppressant compounds and compositions | IRM LLC (BM) | 2009-08-11 | — | — | US | disclosed |
| EP-1718307-A4 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2009-04-29 | — | — | EP | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | IRM LLC (BM) | 2007-08-30 | — | — | US | disclosed |
| EP-1718307-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM, LLC (BM) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082089-A2 | IMMUNOSUPPRESSANT COMPOUNDS AND COMPOSITIONS | IRM LLC (BM) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203100-A1 | Immunosuppressant Compounds and Compositions | ICOS, EDNRA, NFATC1 | S1PR1 133/4885S1PR3 142/4885NOTUM 3843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.